JP2013536858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536858A5 JP2013536858A5 JP2013527262A JP2013527262A JP2013536858A5 JP 2013536858 A5 JP2013536858 A5 JP 2013536858A5 JP 2013527262 A JP2013527262 A JP 2013527262A JP 2013527262 A JP2013527262 A JP 2013527262A JP 2013536858 A5 JP2013536858 A5 JP 2013536858A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- chloro
- methyl
- benzazepine
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 239000002552 dosage form Substances 0.000 claims description 26
- 230000037221 weight management Effects 0.000 claims description 26
- 206010033307 Overweight Diseases 0.000 claims description 15
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 claims description 14
- 235000012054 meals Nutrition 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 235000012631 food intake Nutrition 0.000 claims description 12
- 230000004580 weight loss Effects 0.000 claims description 10
- 239000000883 anti-obesity agent Substances 0.000 claims description 8
- 229940125708 antidiabetic agent Drugs 0.000 claims description 8
- 239000003472 antidiabetic agent Substances 0.000 claims description 8
- 229940125710 antiobesity agent Drugs 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000037406 food intake Effects 0.000 claims description 7
- 230000036186 satiety Effects 0.000 claims description 7
- 235000019627 satiety Nutrition 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 5
- 235000003642 hunger Nutrition 0.000 claims description 5
- 150000004677 hydrates Chemical class 0.000 claims description 5
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 5
- 229960003105 metformin Drugs 0.000 claims description 5
- 201000002859 sleep apnea Diseases 0.000 claims description 5
- JXPLVDIOYCZMCL-QRPNPIFTSA-N (5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine;2-hydroxyacetic acid Chemical compound OCC(O)=O.C[C@H]1CNCCC2=CC=C(Cl)C=C12 JXPLVDIOYCZMCL-QRPNPIFTSA-N 0.000 claims description 4
- QJTAECMTXJHPIE-QRPNPIFTSA-N (5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine;hexanedioic acid Chemical compound OC(=O)CCCCC(O)=O.C[C@H]1CNCCC2=CC=C(Cl)C=C12 QJTAECMTXJHPIE-QRPNPIFTSA-N 0.000 claims description 4
- LBPRUTQSXUUQDQ-QRPNPIFTSA-N (5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine;hydrobromide Chemical compound Br.C[C@H]1CNCCC2=CC=C(Cl)C=C12 LBPRUTQSXUUQDQ-QRPNPIFTSA-N 0.000 claims description 4
- OAKWIZZGLJXXQZ-QRPNPIFTSA-N (5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C[C@H]1CNCCC2=CC=C(Cl)C=C12 OAKWIZZGLJXXQZ-QRPNPIFTSA-N 0.000 claims description 4
- BOKGRJHFZCLFOV-QRPNPIFTSA-N (5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine;nitric acid Chemical compound O[N+]([O-])=O.C[C@H]1CNCCC2=CC=C(Cl)C=C12 BOKGRJHFZCLFOV-QRPNPIFTSA-N 0.000 claims description 4
- PHUPWGHNZALQEV-QRPNPIFTSA-N (5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine;propanedioic acid Chemical compound OC(=O)CC(O)=O.C[C@H]1CNCCC2=CC=C(Cl)C=C12 PHUPWGHNZALQEV-QRPNPIFTSA-N 0.000 claims description 4
- ZEZBZHACNLTZNP-QRPNPIFTSA-N (5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine;sulfuric acid Chemical compound OS(O)(=O)=O.C[C@H]1CNCCC2=CC=C(Cl)C=C12 ZEZBZHACNLTZNP-QRPNPIFTSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000000378 dietary effect Effects 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- VCSZKSHWUBFOOE-UHFFFAOYSA-N dioxidanium;sulfate Chemical compound O.O.OS(O)(=O)=O VCSZKSHWUBFOOE-UHFFFAOYSA-N 0.000 claims description 2
- WRZCAWKMTLRWPR-VSODYHHCSA-N lorcaserin hydrochloride hemihydrate Chemical compound O.Cl.Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12.C[C@H]1CNCCC2=CC=C(Cl)C=C12 WRZCAWKMTLRWPR-VSODYHHCSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 24
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000007726 management method Methods 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 10
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 6
- ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical group CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229950007046 chlorphentermine Drugs 0.000 description 3
- HXCXASJHZQXCKK-UHFFFAOYSA-N clortermine Chemical compound CC(C)(N)CC1=CC=CC=C1Cl HXCXASJHZQXCKK-UHFFFAOYSA-N 0.000 description 3
- 229950000649 clortermine Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- UMWAUEZOGHNSCH-UHFFFAOYSA-N pentorex Chemical compound CC(N)(C)C(C)C1=CC=CC=C1 UMWAUEZOGHNSCH-UHFFFAOYSA-N 0.000 description 3
- 229950000821 pentorex Drugs 0.000 description 3
- 229960003562 phentermine Drugs 0.000 description 3
- 230000037213 diet Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40258910P | 2010-09-01 | 2010-09-01 | |
| US61/402,589 | 2010-09-01 | ||
| PCT/US2011/049953 WO2012030951A1 (en) | 2010-09-01 | 2011-08-31 | Fast-dissolve dosage forms of 5-ht2c agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013536858A JP2013536858A (ja) | 2013-09-26 |
| JP2013536858A5 true JP2013536858A5 (enExample) | 2014-10-16 |
Family
ID=44645827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527262A Pending JP2013536858A (ja) | 2010-09-01 | 2011-08-31 | ５−ｈｔ２ｃアゴニストの速く溶解する剤形 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140148442A1 (enExample) |
| EP (1) | EP2611781A1 (enExample) |
| JP (1) | JP2013536858A (enExample) |
| KR (1) | KR20130138768A (enExample) |
| CN (1) | CN103189358A (enExample) |
| AU (1) | AU2011296027A1 (enExample) |
| CA (1) | CA2808900A1 (enExample) |
| IN (1) | IN2013DN02552A (enExample) |
| MX (1) | MX2013002430A (enExample) |
| SG (2) | SG188363A1 (enExample) |
| WO (1) | WO2012030951A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3485878A1 (en) | 2010-09-01 | 2019-05-22 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
| KR20130138770A (ko) | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 광학적으로 활성 산을 갖는 로르카세린의 염 |
| US8999970B2 (en) | 2010-09-01 | 2015-04-07 | Arena Pharmaceuticals, Inc. | Administration of an anti-obesity compound to individuals with renal impairment |
| SG188361A1 (en) | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Non-hygroscopic salts of 5-ht2c agonists |
| CA2886875A1 (en) | 2012-10-09 | 2014-04-17 | Arena Pharmaceuticals, Inc. | Method of weight management |
| WO2014135545A1 (en) * | 2013-03-05 | 2014-09-12 | Sandoz Ag | Solid dispersion comprising amorphous lorcaserin hydrochloride |
| WO2014187768A1 (en) * | 2013-05-20 | 2014-11-27 | Lek Pharmaceuticals D.D. | Novel synthetic processes to 8-chloro-3-benzo[d]azepine via friedel-crafts alkylation of olefin |
| EP2868656A1 (en) * | 2013-11-05 | 2015-05-06 | LEK Pharmaceuticals d.d. | Stabilized amorphous lorcaserin hydrochloride |
| CN104936947B (zh) * | 2013-12-27 | 2017-03-08 | 杭州普晒医药科技有限公司 | 氯卡色林盐及其晶体、其制备方法和用途 |
| CN105228986B (zh) | 2014-04-21 | 2017-11-07 | 杭州普晒医药科技有限公司 | 一种氯卡色林共晶及其制备方法、药物组合物和用途 |
| CN103901151A (zh) * | 2014-04-23 | 2014-07-02 | 湖北朗昕生化药业有限公司 | 一种hplc法检测氯卡色林盐酸盐含量的方法 |
| WO2016069875A1 (en) | 2014-10-30 | 2016-05-06 | Arena Pharmaceuticals, Inc. | Compositions and methods for ceasing tobacco smoking |
| AU2017290107A1 (en) | 2016-06-29 | 2019-01-17 | CannScience Innovations Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2561916B1 (fr) | 1984-03-30 | 1987-12-11 | Lafon Labor | Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau |
| US4642903A (en) | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
| US5112616A (en) | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
| US5073374A (en) | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
| US5219574A (en) | 1989-09-15 | 1993-06-15 | Cima Labs. Inc. | Magnesium carbonate and oil tableting aid and flavoring additive |
| US5223264A (en) | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
| US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| US5188825A (en) | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
| CA2110575A1 (en) * | 1991-06-21 | 1993-01-07 | John Gerard Ward | Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine |
| US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
| EP0553777B1 (en) | 1992-01-29 | 2002-04-24 | Takeda Chemical Industries, Ltd. | Fast dissolving tablet and its production |
| DE4203932A1 (de) | 1992-02-11 | 1993-08-12 | Deutsche Aerospace | Sende-/empfangsmodul |
| US5503846A (en) | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
| WO1995001782A2 (en) | 1993-07-09 | 1995-01-19 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
| US5851553A (en) | 1993-09-10 | 1998-12-22 | Fuisz Technologies, Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
| US5895664A (en) | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
| US5622719A (en) | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
| US5595761A (en) | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
| US5576014A (en) | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
| US5635210A (en) | 1994-02-03 | 1997-06-03 | The Board Of Regents Of The University Of Oklahoma | Method of making a rapidly dissolving tablet |
| US5567439A (en) | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
| GB9421836D0 (en) | 1994-10-28 | 1994-12-14 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms of hydrophobic substances |
| US5639475A (en) | 1995-02-03 | 1997-06-17 | Eurand America, Incorporated | Effervescent microcapsules |
| US5607697A (en) | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
| US5807577A (en) | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
| US5807578A (en) | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
| HUP0000116A3 (en) | 1996-10-01 | 2000-08-28 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| US5869098A (en) | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| GB0111186D0 (en) * | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
| EP1425577A4 (en) * | 2001-08-10 | 2004-12-29 | Symyx Technologies Inc | APPARATUSES AND METHODS FOR PREPARING AND TESTING PRE-FORMULATIONS AND CORRESPONDING SYSTEMS |
| CA2482195A1 (en) | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| MXPA05013364A (es) * | 2003-06-17 | 2006-03-17 | Arena Pharm Inc | Procedimiento para preparar 3-benzazepinas. |
| US7704993B2 (en) * | 2003-06-17 | 2010-04-27 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| TW200510324A (en) * | 2003-08-11 | 2005-03-16 | Lilly Co Eli | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist |
| US20080009478A1 (en) * | 2003-10-22 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases |
| EA011011B1 (ru) * | 2004-02-25 | 2008-12-30 | Эли Лилли Энд Компани | 6-ЗАМЕЩЁННЫЕ 2,3,4,5-ТЕТРАГИДРО-1H-БЕНЗО[d]АЗЕПИНЫ В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРОВ 5-HT |
| BRPI0519726B8 (pt) | 2004-12-21 | 2021-05-25 | Arena Pharm Inc | composto de hemidrato de (r)-8-cloro-1-metil-2,3,4,5-tetraidro-1h-3-benzazepina, composição compreendendo o referido composto e seus usos |
| BRPI0515862A2 (pt) * | 2004-12-23 | 2011-10-11 | Arena Pharm Inc | uso de fentermina e agonista seletivo do receptor de 5ht-2c na preparação de composições, composições moduladoras do receptor de 5ht-2c e forma de dosagem unitária compreendendo as mesmas |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| JP5237810B2 (ja) * | 2005-09-01 | 2013-07-17 | イーライ リリー アンド カンパニー | ５−ＨＴ２Ｃ受容体アゴニストとしての６−置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン |
| ES2328520T3 (es) * | 2005-09-01 | 2009-11-13 | Eli Lilly And Company | 2,3,4,5-tetrahidro-1h-benzo(d)azepinas 6-sustituidas como agonistas del receptor de 5-ht2c. |
| JP5199997B2 (ja) * | 2006-04-03 | 2013-05-15 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピンおよびこれに関連する中間体を調製するためのプロセス |
| JP5404414B2 (ja) * | 2006-12-05 | 2014-01-29 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンおよびその中間体を調製するための方法 |
| BRPI0806498A2 (pt) | 2007-01-04 | 2014-04-22 | Prosidion Ltd | Agonistas gpcr piperidina |
| US20090143363A1 (en) * | 2007-10-15 | 2009-06-04 | Concert Pharmaceuticals, Inc. | Deuterated lorcaserin |
| US8822727B2 (en) | 2008-03-04 | 2014-09-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| TW201002705A (en) | 2008-03-31 | 2010-01-16 | Metabolex Inc | Oxymethylene aryl compounds and uses thereof |
| CN102203074A (zh) | 2008-06-20 | 2011-09-28 | 麦它波莱克斯股份有限公司 | 芳基gpr119激动剂及其用途 |
| BRPI0919288A2 (pt) | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | teriapia de combinação para tratamento de diabetes e condições relacionadas. |
| NZ596445A (en) | 2009-06-24 | 2013-04-26 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
-
2011
- 2011-08-31 EP EP11755511.0A patent/EP2611781A1/en not_active Withdrawn
- 2011-08-31 AU AU2011296027A patent/AU2011296027A1/en not_active Abandoned
- 2011-08-31 JP JP2013527262A patent/JP2013536858A/ja active Pending
- 2011-08-31 CA CA2808900A patent/CA2808900A1/en not_active Abandoned
- 2011-08-31 CN CN201180052517XA patent/CN103189358A/zh active Pending
- 2011-08-31 SG SG2013015607A patent/SG188363A1/en unknown
- 2011-08-31 KR KR1020137008322A patent/KR20130138768A/ko not_active Withdrawn
- 2011-08-31 SG SG10201506873WA patent/SG10201506873WA/en unknown
- 2011-08-31 IN IN2552DEN2013 patent/IN2013DN02552A/en unknown
- 2011-08-31 US US13/820,123 patent/US20140148442A1/en not_active Abandoned
- 2011-08-31 MX MX2013002430A patent/MX2013002430A/es not_active Application Discontinuation
- 2011-08-31 WO PCT/US2011/049953 patent/WO2012030951A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013539470A5 (enExample) | ||
| JP2013536857A5 (enExample) | ||
| JP2013536859A5 (enExample) | ||
| JP2012006970A5 (enExample) | ||
| JP2006143751A5 (enExample) | ||
| JP2009530394A (ja) | アミノ酸ベースの医用食品を用いて薬剤を増強するための方法および組成物 | |
| JP2009542699A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| JP2013541595A5 (enExample) | ||
| CA2890699A1 (en) | Combination therapy | |
| WO2016126707A1 (en) | Apilimod compositions and methods for using same | |
| AU2023220976A1 (en) | Neuroactive steroids for treatment of cns-related disorders | |
| Rodríguez et al. | Past, present, and future of pharmacologic therapy in obesity | |
| JP2013536858A (ja) | ５−ｈｔ２ｃアゴニストの速く溶解する剤形 | |
| MY139107A (en) | Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments. | |
| KR20150070249A (ko) | 체중 관리 방법 | |
| JP2013536859A (ja) | ５−ｈｔ２ｃアゴニストの非吸湿性塩 | |
| JP2013531073A5 (enExample) | ||
| CN112955145A (zh) | 使用苯氧丙胺化合物治疗疼痛的方法 | |
| KR101848722B1 (ko) | 게실증의 치료를 위한 방법 및 조성물 | |
| SI2200980T1 (sl) | Aminoarilsufonamidne spojine in njihova uporaba kot 5-HT6 ligandi | |
| JP2008189616A (ja) | 注意欠陥多動性障害の治療薬 | |
| JP2011178702A (ja) | 睡眠の改善剤 | |
| Howland | Therapies for obesity and medication-associated weight gain | |
| TW201032805A (en) | Pharmaceutical compositions comprising a compound having suppressive effect on nutrient digestion or absorption and a cyclohexanecarboxamide derivative |